Abstract

Introduction: Artificial intelligence (AI) has the potential to revolutionize drug design and discovery by significantly reducing the time and costs involved in developing new drugs. This literature review aims to explore the use of AI in drug design, focusing on virtual screening, de novo drug design, and prediction of ADME properties. Objective: The objective of this review is to provide an overview of the AI techniques used in drug design and their applications in virtual screening, de novo drug design, and prediction of ADME properties. The review also aims to summarize the advantages and limitations of these approaches and present case studies and examples showcasing their use in drug design. Methodology: A comprehensive search of academic databases was conducted, and 11 relevant articles were selected for inclusion in this review. The selected articles were analyzed to identify the AI techniques used in drug design, their applications, advantages, and limitations. Case studies and examples were also examined to demonstrate the efficacy of AI in drug design. Results: AI techniques such as machine learning, deep learning, and reinforcement learning have been successfully used in virtual screening, de novo drug design, and prediction of ADME properties. Virtual screening involves the use of AI algorithms to identify promising compounds for further testing, while de novo drug design involves the generation of novel compounds using AI techniques. Prediction of ADME properties involves the use of AI to predict the absorption, distribution, metabolism, and excretion of drug candidates. The case studies and examples presented in this review demonstrate the potential of AI to accelerate drug design and discovery. Conclusion: AI has the potential to revolutionize drug design and discovery by significantly reducing the time and costs involved in developing new drugs. Virtual screening, de novo drug design, and prediction of ADME properties are among the most promising applications of AI in drug design. However, further research is needed to fully explore the potential of AI in drug design and overcome some of the limitations of current approaches. Keywords: Artificial Intelligence; Drug Design; Virtual Screening; De Novo Drug Design; ADME Prediction

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.